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Abstract 
 
Purpose: Outpatient parenteral antimicrobial therapy (OPAT) is a therapeutic option meant to 
conserve healthcare resources when treating infections requiring the administration of IV 
antibiotics over a prolonged treatment course. In November 2016 at Franciscan Alliance 
Indianapolis, a dedicated pharmacist was hired to build a formal OPAT program for all patients 
discharged on IV antimicrobials under the care of the infectious disease physician group. The 
number of “good catch” events observed since the program’s formal inception has encouraged 
the creation of this study designed to examine the impact of this program on patient outcomes 
and antimicrobial stewardship.  
 
Methods: This was a retrospective chart review of adult patients with a discharge order for at 
least one IV antibiotic from Franciscan Health Indianapolis from December 1st, 2016 to May 
31st, 2017. Patients receiving OPAT consults during their index hospital stay were compared to 
patients with similar infections who did not receive a consult.  Patients residing in a nursing 
home or long-term care facility prior to admission were excluded from the analysis. Comparisons 
between patients with and without a readmission were also conducted in order to identify 
commonalities and differences in risk factors between groups. Demographic information 
collected included: the indication for parenteral antimicrobial therapy, sex, age, weight, and the 
type of provider prescribing the antimicrobials. The primary objective was 30-day readmission 
rate, with each instance being stratified based on the reason for readmission. Secondary 
objectives included: type of infection, antibiotic type, disposition at discharge, and duration of 
treatment. At least 122 patients were needed in each arm in order to detect a difference of 50 
percent between treatment groups with a power of 80 percent for the primary objective.  
 
Results: No statistically significant difference between the readmission rates of the consult 
group and the non-consult group was observed (14.73% versus 31.82%, p>0.05). The usage of 
antipseudomonal coverage (39.58% versus 86.36%, p<0.0001) and ceftriaxone (9.47% versus 
45.45%, p<0.0001) was significantly lower in the consult group, demonstrating the potential 
improvements in antimicrobial stewardship an OPAT program can provide. Use of agents 
requiring therapeutic drug monitoring (TDM) was higher in the non-consult group, specifically 
vancomycin (86.36% versus 41.05%, p<0.001) and gentamicin (6.32% versus 22.73%, p<0.05). 
Furthermore, patients discharged to an extended care facility (ECF) or a short-term acute 
rehabilitation center (SAR) after receiving a consult were less likely to be readmitted (16.23% 
versus 54.55%, p<0.001). The difference in use of drugs requiring TDM for patients sent to a 
SAR with a consult may also have contributed to this trend (50.46% versus 100%, p<0.0001).  
 
Conclusion: The OPAT service did not show a statistically significantly reduction in the 30-day 
readmission rate during the first 6 months of the program. However, the number of patients 
without a consult meeting the inclusion criteria was markedly lower than anticipated, which led 
to the study being underpowered. Additionally, use of the program was associated with improved 
antimicrobial stewardship through reduced use of antipseudomonal coverage and ceftriaxone as 
well as reduced readmissions in patients requiring SAR placement.  
 
 
 
  
 
  
 
Background  
Outpatient parenteral antimicrobial therapy (OPAT) is defined as the administration of 
parenteral antimicrobials for at least 2 doses given on different days and without a hospitalization 
between.1 Rather than requiring a patient to remain in a hospital solely to receive antimicrobial 
therapy after being medically cleared to go home, he or she can be discharged for a portion of the 
therapy. The ability to send a patient on intravenous antimicrobial therapy has been shown to 
potentially reduce the high costs associated with chronic administration of antibiotics,2 increase 
the patient’s quality of life by granting improved flexibility and convenience, and reduce the 
likelihood that the patient will acquire a nosocomial infection. As a result, OPAT has grown at a 
breakneck pace since its inception in the 1970s, and projections of its market share predict that it 
will soon reach the multibillion-dollar-a-year threshold.1  
 Furthermore, input from pharmacists to assist in the appropriate selection of 
antimicrobials and durations of therapies has the potential to attempt to stem the rising tide of 
resistant microorganisms. The interventions related to spectrum and duration can lead to vastly 
reduced rates of adverse effects due to unnecessary antimicrobial use and can also reduce the 
likelihood that the patient may encounter an infection caused by a resistant organism later in 
life.3 Additionally, it may reduce the rate of multidrug resistant organisms, which is especially 
critical for patients who must be admitted but are also most at risk. Through appropriate 
recommendations related to the spectrum and duration of therapy, selection of resistant 
microorganisms can be minimized, which partially mitigates these risks. 
 In addition to pharmacist involvement, interprofessional collaboration and careful 
selection of patients designated to receive OPAT are critical to ensuring successful therapy. 
Beyond the clinical expertise offered by the ID physicians, coordination of social support and 
third-party authorizations between case management and pharmacy contribute significantly to a 
patient’s ability to receive appropriate therapy. Additionally, in patients for whom adequate 
monitoring and follow up cannot be guaranteed, complications related to vascular access devices 
and drug adverse reactions can lead to significant harm.4 Therefore, both social and medical 
evaluations should be integral steps in the process utilized to identify patients appropriate to 
receive OPAT. 
 In November 2016 at a community hospital, a dedicated pharmacist was hired to continue 
to build a formal OPAT program for all patients discharged on IV antimicrobials under the care 
of the infectious disease physician group. Through a collaborative practice agreement, the 
pharmacist’s responsibilities upon consultation were to evaluate and make recommendations 
related to antimicrobial selection, therapy duration, and monitoring parameters, as well as the 
provision of patient education and assistance to case managers involved with disposition 
planning. Upon discharge from the hospital, the pharmacist continued weekly monitoring 
throughout the duration of therapy of all patients that received such consultative services during 
their inpatient stay. Due to the relatively new nature of this OPAT program and the number of 
“good catch” events observed since its formal inception, this study sought to examine the impact 
of an OPAT program for those patients receiving OPAT at hospital discharge.  
 
Methods 
This was a retrospective observational cohort study examining adult patients with an 
order for an IV antibiotic following discharge from a community hospital within the time period 
of December 1, 2016 to May 31, 2017. Patients who received OPAT consults during their index 
hospital stay were compared to those patients who did not in the same time period.  Patients 
  
 
  
 
residing in a nursing home or long-term care facility prior to admission and those also receiving 
oral antimicrobials were excluded from the analysis. The primary objective was thirty-day 
readmission rate, which was stratified by the reason for readmission (ID process, drug adverse 
event, or unrelated reason). Type of infection, antimicrobial selection (including agents with 
antipseudomonal activity or requiring therapeutic drug monitoring), duration of treatment, and 
disposition at hospital discharge were also collected from the electronic medical record.  
 
Statistical Analysis 
The Fisher’s Exact Test and Chi Square Analyses were utilized, as appropriate, for 
nominal endpoints including: the 30-day readmission rate, use of each antimicrobial class, and 
the use of agents with a high risk of a C. difficile infection, such as ceftriaxone, or requiring 
therapeutic drug monitoring. The Wilcoxon Ranked Sum Test was utilized to determine the 
significance of differences in length of stay and duration of therapy. Statistical Package for the 
Social Sciences software available through Butler University was utilized for these analyses. All 
other variables and baseline demographic information were described utilizing descriptive 
statistics. 
 
Results 
No statistically significant differences between groups were seen in terms of 
demographic information (Table 1).  
 
Table 1: Demographics 
 
 OPAT 
Consult 
(N=95) 
No OPAT 
Consult 
(N=22) 
p Value 
Median Age 
(IQR) 
61 (21) 63 (26) 0.503 
Sex (%) 
     M 
     F 
 
42 (44) 
53 (56) 
 
6 (27) 
16 (73) 
 
0.146 
Median 
Weight 
(IQR) 
  
 91 kg  
(35 kg) 
 
79 kg  
(41 kg) 
 
0.085 
Median 
Index LOS 
(IQR) 
 
6 (5) 
 
7 (8) 
 
0.313 
 
No statistically significant difference between the readmission rates of the OPAT consult 
group and the non-consult group was observed (14.73% vs 31.82%, p=0.07). Additionally, the 
proportion of patients requiring a change in disposition did not vary significantly between 
groups, with 39 (41%) patients with a consult and 12 (55%) patients without a consult being 
discharged to a short-term acute rehabilitation center (SAR) or extended care facility (ECF) 
(P=0.252). Bacteremias with various sources of infection were the most common type of 
infection requiring therapy in both groups, constituting 35% of patients in the OPAT consult 
group and 59% of the patients without a consult. Differences in provider type and indication for 
  
 
  
 
therapy between groups were statistically significant (p=<<0.0001; 3 x 10-12). The median total 
days of therapy for patients with a consult was 24 days in comparison to 25 days in the non-
consult group (p=0.095).  
The most significantly differing trends between groups were evident in prescribing 
practices. The usage of antipseudomonal coverage was significantly lower in the OPAT consult 
group (39.58% vs 86.36%, p=0.00006). Additionally, utilization of ceftriaxone, known for its 
potential to predispose patients to C. difficile infections, was also significantly lower in the 
OPAT consult group (9.47% vs 45.45%, p=0.00004). Differences in other key antibiotics that 
serve as stewardship targets were also seen with piperacillin-tazobactam, cefepime, and 
vancomycin (Table 2). Also of interest, patients without an OPAT consult discharged to a SAR 
or ECF were significantly more likely to have been prescribed agents requiring therapeutic drug 
monitoring (100% vs 59.56%, p=0.038) and to have later required readmission (54.55% vs 
16.22%, p=0.001). 
 
Table 2: All Patients 
 
 OPAT Consult 
(N=95) 
No OPAT Consult  
(N=22) 
p Value 
Disposition Change 39 (41%) 12 (55%) 0.252 
Indication for Therapy 
     Empyema 
     Osteomyelitis 
     Bacteremia 
     Intra-Abdominal 
     Skin and Soft Tissue (SSTI) 
     Other 
 
7 
11 
33 
10 
25 
9 
 
2 
2 
13 
3 
0 
2 
3 x 10-12 
 
Primary Provider Type 
     Pulmonary 
     Cardiology 
     Surgery 
     Internal Medicine 
     Oncology 
 
5  
10  
25  
52  
3  
 
7  
1 
4 
8 
2 
0.000095 
 
Median Days of Therapy 
(IQR) 
24 (19) 25 (17) 0.095 
 
 
 
 
 
 
 
 
  
 
  
 
Table 3: Drug Choice 
 
Drug Choice      OPAT Consult  
(N=95) 
No OPAT Consult 
(N=22) 
P Value 
Ampicillin 5 2 0.495 
Ampicillin-Sulbactam 12 2 0.645 
Piperacillin-Tazobactam 13 11 0.0001 
Cefazolin 15 3 0.801 
Ceftazidime 1 0 0.203 
Ceftriaxone 9 10 0.00004 
Cefuroxime 1 1 0.255 
Cefepime 10 7 0.011 
Meropenem 8 5 0.054 
Ertapenem 4 1 0.944 
Gentamicin 6 5 0.017 
Tobramycin 0 4 0.0002 
Vancomycin 39 19 0.0001 
Linezolid 0 2 0.023 
Daptomycin 1 0 0.213 
Metronidazole 2 5 0.0002 
Clindamycin 2 2 0.104 
Fluconazole 2 2 0.104 
Antipseudomonal Agents 37 19 0.00006 
 
Readmitted Subgroup 
 When examining readmitted patients as a subgroup, several differences between those 
receiving a consult and those without were seen (Table 4). Significant differences in the 
indications for therapy in this population were seen (p=0.009), with bacteremias and SSTIs as the 
most common in the OPAT consult (71%) and non-consult (43%) groups, respectively. 
Additionally, a trend was seen showing that patients in this subgroup without a consult were 
more likely to have experienced a change in disposition (85.71% vs 42.86%, p=0.061). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
  
 
Table 4: Readmitted Patients 
 
 OPAT 
Consult  
(N=14) 
No  
OPAT Consult  
(N=7) 
P Value 
Median Age (IQR) 61 (16) 64 (26) 0.711 
Sex 
     Male 
     Female 
 
8  
6  
 
5  
2  
 
0.525 
Indication for Therapy 
     Osteomyelitis 
     Bacteremia 
     Intra-Abdominal 
     Skin and Soft Tissue 
     Other 
 
2 
3 
2 
6 
1 
 
1 
5 
1 
0 
0 
0.009 
 
Median Index Length 
of Stay (IQR) 
6 (2) 7 (3) 0.352 
Median Days to 
Readmission (IQR) 
12 (14) 9 (6) 0.368 
Disposition at 
Discharge 
     Home 
     ECF or SAR 
 
 
8 
6 
 
 
1 
6 
 
0.061 
 
Disposition Change 6 (43%) 6 (86%) 0.061 
Median Total Days of 
Therapy (IQR) 
28 (24) 28 (27) 0.190 
Reason for 
Readmission 
     ID Process 
     Drug Adverse Event 
     Unrelated Process 
 
 
2 
3 
9 
 
 
3 
1 
3 
 
0.216 
 
 
 
Discussion 
No statistical significance in terms of the primary objective, thirty-day readmission rates, 
was seen in the study. However, the more than two-fold difference in readmission rate can 
certainly be seen as clinically significant. The readmission rate of 14.74% was also similar to the 
21.5% readmission rate reported by another study, which somewhat adds to the confidence with 
which the results from this study can be interpreted.5   
  
 
  
 
Considerable improvements in antimicrobial stewardship were seen when comparing the 
group of patients receiving a consult to those that did not. This enhancement in stewardship was 
primarily via reduced utilization of antipseudomonal coverage, vancomycin, and ceftriaxone, 
which demonstrated the key role that such programs can have on selecting therapy with an 
appropriately narrow spectrum. One way by which OPAT can reduce costs and improve patient 
outcomes comes via the involvement of infectious disease specialists to improve the selection of 
appropriately narrow spectrum antimicrobials. By avoiding the use of overly broad coverage, the 
risk of off target eradication of the gut microbiome and subsequent development of a Clostridium 
difficile infection can be significantly reduced. Beyond the clinical impact of this variety of 
infectious diarrhea, this microbe leads to 4.8 billion dollars in additional costs to hospitals in the 
United States annually.6 For example, unnecessary use of ceftriaxone, a cephalosporin utilized 
for a variety of infections, has become a potential target for antimicrobial stewardship programs 
due to its common use and propensity for causing this type of infection.6,7 It is imperative that 
therapies are selected appropriately to only cover the types of microorganisms likely to be 
causing the patient’s infection, and narrowed when culture and susceptibility data are available, 
which is a major point of impact for pharmacist-led OPAT services. 
The difference in readmissions seen for patients without a consult sent to a SAR or ECF 
highlights the value of including a dedicated infectious disease clinical pharmacy specialist to 
coordinate careful monitoring during the course of OPAT. Especially when utilizing agents 
requiring therapeutic drug monitoring, such as vancomycin or aminoglycosides, the potential for 
significant adverse effects is considerable, and lack of lab value availability during the course of 
OPAT has been noted to be a significant risk factor for readmission, which may partially explain 
the difference seen here.8 The potentially increased debility or acuity of patients more likely to 
be sent to a SAR or ECF in comparison to a patient able to be sent home could have contributed 
to this observation, but such a difference was not seen amongst patients sent to these facilities 
after receiving a consult. 
The need for appropriate monitoring and communication between healthcare systems 
should be given careful consideration prior to the implementation of OPAT. One report noted 
that 26% of sites surveyed had a team specifically designated to handle OPAT cases.5 A survey 
of practitioners involved in an OPAT service indicated that up to 70% had seen such therapy 
implemented without a consult from an ID specialist, and another study showed the addition of a 
pharmacist or ID physician or pharmacist to an OPAT team raised adherence to monitoring by 
32% and 64%, respectively.9, 10 One study showed that cases reviewed by an ID physician led to 
changes in therapy from parenteral to oral agents in 27-40% of cases.9 This shows the value of a 
dedicated OPAT team’s ability to improve patient care via appropriate selection of antimicrobial 
therapy from a therapeutic perspective, which often reduces costs.  
While poor communication can be a barrier to the success of OPAT, adverse effects have 
been cited as the primary reason for OPAT discontinuation or therapy modification in 3-5% of 
cases.9 A survey of infectious disease physicians conducted in 2012 showed that only 22% of the 
OPAT programs in which they worked had a way to track medication errors, “near misses”, or 
adverse events.5 Additionally, it is of utmost importance that patients who are to receive OPAT 
be carefully selected to ensure that they have to appropriate social and financial support to 
receive therapy at home, an infusion center, or another location. The potential ramifications for 
patients inappropriately selected for outpatient therapy include both clinical decompensation as 
well as the potential for enhanced resistance by the responsible pathogen due to incomplete 
eradication.  
  
 
  
 
Several limitations should be considered when interpreting the results of the study. The 
small sample size and timing of the study period at the advent of the program could have 
impacted the results. Additionally, the significantly lower number of eligible non-consult 
patients noted previously was a phenomenon that should also be considered. This trend could 
possibly have been due to the novelty of the new program or increased provider confidence in 
the utilization of a formalized OPAT program able to more consistently offer improved 
monitoring and follow up after discharge. The lack of assessments related to comorbidities, 
severity of infection, or causative pathogen limit the generalizability of these findings. Finally, 
due to the method by which cost data for the non-consult was requested, namely via use of ICD-
10 coding, a certain level of uncertainty was introduced. It was hypothesized that this may have 
been due to inconsistent coding practices and likely did not skew the results in favor of either 
group, but it should be noted nonetheless. 
As OPAT services continue to expand in the United States, further investigations 
utilizing larger sample sizes and examining shifting trends in patient outcomes should be 
conducted in order to further assess the value of the program and monitor for potential quality 
improvement opportunities. Furthermore, patient and provider satisfaction data could be included 
to better assess the improvements in quality of life and perception of value associated with the 
program, respectively. This study serves as a promising indication for the potential patient care 
improvements related to antimicrobial stewardship and improved patient outcomes that OPAT 
services can offer to their patients. 
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